A phase II, randomised, partially-blinded, cross over study to evaluate the systemic effect of two doses of the SMB BUDESONIDE-SALMETEROL DPI fixed-dose combination capsule (300/25 microg BID and 150/25 microg BID) delivered by the AXAHALER versus PULMICORT TURBOHALER 400microg BID and SEREVENT DISKUS 50microg BID versus placebo in mild persistent asthmatic patients.

Trial Profile

A phase II, randomised, partially-blinded, cross over study to evaluate the systemic effect of two doses of the SMB BUDESONIDE-SALMETEROL DPI fixed-dose combination capsule (300/25 microg BID and 150/25 microg BID) delivered by the AXAHALER versus PULMICORT TURBOHALER 400microg BID and SEREVENT DISKUS 50microg BID versus placebo in mild persistent asthmatic patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2011

At a glance

  • Drugs Budesonide; Budesonide/salmeterol; Salmeterol
  • Indications Asthma
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 24 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top